Further investigations of cytotoxic behavior in CD19+ may address, for instance, eventual important mechanisms associated with the clinical efficacy of emerging anti-CD19 mAbs and oral drugs targeting Bruton’s tyrosine kinase (BTK) for MS patients (45). This evidence concerns the gene CD19 and myeloid sarcoma.